Actithera

News

A new player in radioligand therapies, Actithera, has arrived on the scene with $75.5m in funding and lead FAP-targeted candidate for cancer.

Oncology

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.